# A Phase 1/ Phase 2 Study of TTHX1114(NM141)

> **NCT04520321** · PHASE1,PHASE2 · COMPLETED · sponsor: **Trefoil Therapeutics, Inc.** · enrollment: 22 (actual)

## Conditions studied

- Corneal Endothelial Dystrophy
- Fuchs Endothelial Corneal Dystrophy
- Pseudophakic Bullous Keratopathy
- Endothelial Dysfunction

## Interventions

- **DRUG:** TTHX1114(NM141)
- **OTHER:** Vehicle (placebo)

## Key facts

- **NCT ID:** NCT04520321
- **Lead sponsor:** Trefoil Therapeutics, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-08-19
- **Primary completion:** 2021-04-23
- **Final completion:** 2021-05-18
- **Target enrollment:** 22 (ACTUAL)
- **Last updated:** 2023-10-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04520321

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04520321, "A Phase 1/ Phase 2 Study of TTHX1114(NM141)". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT04520321. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*